BIP (Binding Immunoglobulin Protein), also known as GRP78 (Glucose-Regulated Protein 78) and encoded by the HSPA5 gene, is a major endoplasmic reticulum (ER) chaperone and a key regulator of the unfolded protein response (UPR). BIP maintains ER homeostasis by assisting protein folding, preventing protein aggregation, and regulating UPR signaling through PERK, IRE1, and ATF6 sensors. This page covers the gene's normal function, disease associations, expression patterns, and key research findings relevant to neurodegeneration.
| Symbol | HSPA5 (BIP, GRP78) |
|---|
| Full Name | Heat Shock Protein Family A (Hsp70) Member 5 |
|---|
| Chromosomal Location | 9q33.3 |
|---|
| NCBI Gene ID | 3309 |
|---|
| OMIM | 138120 |
|---|
| Ensembl ID | ENSG00000144566 |
|---|
| UniProt | P11021 |
|---|
| Associated Diseases | [Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), [ALS](/diseases/amyotrophic-lateral-sclerosis) |
|---|
BIP/GRP78 is a 654-amino acid Hsp70 family chaperone localized to the ER lumen. Its primary functions include:
- Protein folding assistance: BIP binds to nascent polypeptides and ensures proper folding by preventing aggregation
- ER quality control: BIP monitors protein folding status and targets misfolded proteins for degradation
- UPR regulation: BIP acts as the primary sensor for ER stress, controlling activation of three UPR branches:
- PERK (Protein kinase R-like ER kinase)
- IRE1 (Inositol-requiring enzyme 1)
- ATF6 (Activating transcription factor 6)
- Calcium binding: BIP has calcium-binding capacity and helps maintain ER calcium homeostasis
BIP is significantly upregulated in AD brain as a protective response to ER stress. Key associations include:
The ER stress response mediated by BIP is critical for survival of dopaminergic neurons:
- Activation of UPR linked to alpha-synuclein pathology
- BIP upregulation in PD substantia nigra neurons
- Role in protein quality control for alpha-synuclein clearance
- Mitochondrial dysfunction intersects with ER stress pathways
BIP upregulation is a hallmark in motor neurons with protein aggregates:
- Detected in ALS spinal cord motor neurons
- Co-localizes with ubiquitin inclusions
- UPR activation as marker of ER stress
- Interaction with TDP-43 pathology
- Prion Disease: BIP involved in clearance of misfolded prion protein
- Ischemia: BIP is neuroprotective in cerebral ischemia through UPR-mediated adaptive responses
- Huntington's Disease: BIP modulates mutant huntingtin aggregation
¶ ER Stress Sensing and Signaling
BIP serves as the master regulator of the three major UPR branches:
PERK Pathway: Under ER stress, BIP releases PERK, allowing its autophosphorylation and activation. PERK then phosphorylates eIF2α, leading to global translation attenuation while selectively translating ATF4. ATF4 upregulates genes involved in amino acid metabolism, antioxidant responses, and apoptosis regulation including CHOP.
IRE1 Pathway: Release of BIP from IRE1 leads to IRE1 oligomerization and autophosphorylation. The activated IRE1 endoribonuclease domain splices XBP1 mRNA, producing XBP1s, a potent transcription factor that upregulates ER chaperones including BIP itself, and genes involved in protein folding, quality control, and ER-associated degradation (ERAD).
ATF6 Pathway: BIP release allows ATF6 to traffic to the Golgi, where it is cleaved by S1P and S2P proteases. The cleaved ATF6 fragment (ATF6f) acts as a transcription factor, activating BIP, XBP1, and other UPR target genes.
Chronic ER stress leads to pro-apoptotic signaling through CHOP (GADD153), a transcription factor induced by all three UPR branches. CHOP promotes apoptosis through:
- Downregulation of Bcl-2 family proteins
- Induction of ERO1α and IP3R, leading to calcium overload
- Activation of GADD34, which dephosphorylates eIF2α and promotes protein synthesis in stressed cells
Beyond its role in UPR signaling, BIP directly participates in protein quality control:
- Folding assistance: BIP's ATPase activity, coordinated by J-domain proteins, helps fold nascent polypeptides
- ERAD: BIP targets misfolded proteins for retrotranslocation to the cytosol and proteasomal degradation
- Autophagy: BIP can target protein aggregates for autophagic clearance when proteasomal degradation is overwhelmed
¶ BIP and Specific Protein Pathologies
In Alzheimer's disease, BIP interacts with various components of the amyloid pathway:
- BIP binds to APP in the ER and may influence its folding and trafficking
- The chaperone activity of BIP helps clear Aβ oligomers
- BIP upregulation in AD may represent a compensatory neuroprotective response
- Therapeutic approaches aim to enhance BIP-mediated Aβ clearance
¶ Alpha-Synuclein Handling
In Parkinson's disease, BIP plays a critical role in handling alpha-synuclein:
- ER stress in dopaminergic neurons triggers BIP upregulation
- BIP may assist in refolding or targeting α-synuclein for degradation
- The BIP/CHOP axis can be activated by α-synuclein accumulation
- Impaired BIP function contributes to α-synuclein aggregation and Lewy body formation
In ALS, BIP interacts with TDP-43 pathology:
- TDP-43 inclusions in motor neurons are accompanied by BIP upregulation
- BIP may help target TDP-43 aggregates for clearance
- The UPR is activated as an early response to TDP-43 mislocalization
Several classes of BIP modulators are being explored:
BIP Inducers:
- TUDCA (tauroursodeoxycholic acid): Enhances BIP expression and has entered clinical trials for AD and PD
- Sodium butyrate: HDAC inhibitor that upregulates BIP
- Geranylgeranylacetone: Induces BIP expression and has shown neuroprotective effects
ER Stress Modulators:
- Salubrinal: Inhibits eIF2α dephosphorylation, enhancing the adaptive UPR
- Guanabenz: Inhibits GADD34 and promotes pro-survival signaling
- Viral vector-mediated BIP overexpression in affected brain regions
- CRISPR-based approaches to enhance BIP expression
- Cell-type specific targeting to dopaminergic neurons or motor neurons
BIP has been investigated as a biomarker for ER stress:
- CSF BIP levels correlate with disease progression in AD and PD
- Peripheral blood monocyte BIP expression may serve as a biomarker
- PET ligands targeting BIP are under development
Constitutively expressed in all cell types, with strong induction under ER stress conditions. High expression in brain, especially in neurons. Localizes to ER lumen. The BIP promoter responds to multiple stress signals including:
- Glucose deprivation
- Calcium depletion
- Hypoxia
- Oxidative stress
BIP shows region-specific expression patterns in the brain:
- Hippocampus: High expression in CA1-CA3 pyramidal neurons and dentate gyrus granule cells
- Cerebral cortex: Strong expression in layer 5 pyramidal neurons
- Substantia nigra: Moderate expression in dopaminergic neurons
- Cerebellum: High expression in Purkinje cells and granule cells
- Spinal cord: Expression in motor neurons
BIP is primarily localized to the ER lumen, but can be found at the cell surface under certain conditions:
- Classical ER lumen localization via KDEL retention signal
- Cell surface expression in cancer cells and stressed neurons
- Secreted form detected in biological fluids
- Mitochondria-associated ER membranes (MAMs)
- Sundaram et al., BIP in neurodegeneration (2018)
- Martinez et al., ER stress in Alzheimer's disease (2019)
- Gething & Sambrook, BiP function in secretory pathway (1999)
- Katayama et al., ER stress in AD (1999)
- Hoozemans et al., UPR in AD (2006)
- Soo et al., GRP78 in PD (2008)
- Preston et al., GRP78 therapeutic target (2009)
- Gorbatyuk et al., UPR in PD (2008)
- Lee et al., GRP78 neuroprotection (2005)
- Sato et al., BIP/CHOP interaction (2009)
¶ Protein Structure and Molecular Mechanism
BIP/GRP78 is a 654-amino acid protein belonging to the Hsp70 (Heat Shock Protein 70) family. The protein contains several distinct domains that enable its chaperone functions:
- N-terminal ATPase domain (residues 1-384): This domain binds and hydrolyzes ATP, providing the energy for BIP's chaperone activity. The ATP-bound state has low substrate affinity, while the ADP-bound state has high affinity for unfolded proteins.
- Substrate-binding domain (SBD) (residues 415-654): This domain binds to hydrophobic peptide segments that are exposed in misfolded proteins. The SBD contains a lid structure that closes over the substrate when BIP is bound.
- C-terminal ER retention signal (KDEL): The sequence KDEL (Lys-Asp-Glu-Leu) at the C-terminus ensures BIP remains localized to the ER lumen.
BIP's chaperone activity is regulated by an ATP-dependent cycle:
- ATP-bound BIP has an open conformation and rapidly binds to nascent polypeptides entering the ER
- ATP hydrolysis to ADP triggers a conformational change that closes the SBD lid, trapping the substrate
- ADP-bound BIP protects the substrate from aggregation and facilitates proper folding
- ATP exchange (replacement of ADP with ATP) releases the folded protein
This cycle is essential for ER protein folding quality control and is regulated by co-chaperones including ERdj proteins (DNAJ domain-containing proteins in the ER).
BIP possesses calcium-binding capacity that is distinct from its chaperone function. The protein can bind approximately 10 moles of calcium per mole of protein. This calcium-binding ability contributes to ER calcium homeostasis and may play a role in calcium-dependent signaling during ER stress.
BIP acts as the master regulator of the unfolded protein response by controlling three distinct ER stress sensors:
PERK (Protein kinase R-like ER kinase):
- BIP binds to PERK's luminal domain under normal conditions
- During ER stress, BIP dissociates from PERK, allowing PERK autophosphorylation
- Activated PERK phosphorylates eIF2α, globally reducing protein translation
- However, selective translation of ATF4 and other stress response genes continues
- PERK activation can lead to pro-apoptotic signaling through CHOP (GADD153)
IRE1 (Inositol-requiring enzyme 1):
- BIP binding maintains IRE1 in an inactive state
- Upon BIP dissociation, IRE1 oligomerizes and autophosphorylates
- Activated IRE1 splices XBP1 mRNA, producing XBP1s (spliced form)
- XBP1s is a transcription factor that upregulates UPR target genes including BIP itself
- IRE1 also has RNase activity that can degrade ER-localized mRNAs (RIDD)
ATF6 (Activating transcription factor 6):
- BIP binds to ATF6's luminal domain, preventing its activation
- During ER stress, ATF6 traffics to the Golgi where it is cleaved
- The cleaved cytosolic fragment (ATF6f) acts as a transcription factor
- ATF6f upregulates UPR genes including XBP1, CHOP, and ER chaperones
BIP expression is dramatically induced during ER stress as part of the adaptive UPR. This upregulation is mediated by:
- XBP1s binding to the BIP promoter
- ATF6f binding to ER stress response elements (ERSE)
- Autoregulation through the UPR feedback loop
The induction of BIP represents a critical adaptive response that restores ER homeostasis. However, in chronic neurodegenerative conditions, this adaptive capacity becomes overwhelmed.
BIP directly interacts with APP and influences its proteolytic processing:
- BIP binds to APP in the ER and affects its folding and trafficking
- Reduced BIP levels lead to increased amyloid-beta production
- BIP overexpression reduces amyloid-beta secretion
- The interaction between BIP and APP involves the protein's ATPase domain
- BIP may facilitate proper APP folding, reducing ER stress signals
In Parkinson's Disease, BIP plays a crucial role in managing alpha-synuclein pathology:
- Alpha-synuclein aggregation causes ER stress
- BIP upregulation is observed in PD brains, particularly in dopaminergic neurons
- BIP can bind to alpha-synuclein and prevent its aggregation
- The IRE1-XBP1 pathway enhances BIP expression to combat alpha-synuclein toxicity
- Loss of BIP function leads to increased alpha-synuclein aggregation
BIP is involved in tau protein metabolism in Alzheimer's disease:
- ER stress affects tau phosphorylation through multiple kinases
- BIP modulates the activity of glycogen synthase kinase-3 beta (GSK3β)
- UPR activation can alter tau seeding and propagation
- BIP expression correlates with tau pathology in AD brain samples
¶ Animal Models and Experimental Findings
BIP knockout in mice is embryonic lethal, demonstrating its essential role in development. Conditional knockout models have revealed:
- Neuron-specific BIP deletion leads to progressive neurodegeneration
- Neurons show increased susceptibility to ER stress-induced apoptosis
- Accumulation of ubiquitinated protein aggregates
- Memory deficits in conditional knockout mice
Transgenic overexpression of BIP shows protective effects:
- Reduced amyloid-beta plaque formation in APP transgenic mice
- Protection against MPTP-induced dopaminergic neuron death (PD model)
- Improved motor performance in ALS models
- Reduced tau pathology in tauopathy models
Small molecules that upregulate BIP show therapeutic potential:
- TUDCA (Tauroursodeoxycholic acid): Increases BIP expression
- Sodium valproate: Upregulates BIP through histone deacetylase inhibition
- Geldanamycin derivatives: Activate HSF1 and increase BIP expression
- BIP-inducing compounds: Currently in development for neurodegenerative diseases
BIP has been investigated as a biomarker for ER stress in neurodegenerative diseases:
- CSF BIP levels: Elevated in AD and PD patients compared to controls
- Blood BIP: Peripheral monocyte BIP expression correlates with disease severity
- Brain imaging: PET ligands for BIP are in development
- Challenge tests: BIP response to stress challenges may predict disease progression
Recent research has revealed important interactions between BIP and microglial function:
- Microglial BIP expression increases with age
- ER stress in microglia contributes to neuroinflammation
- BIP modulates microglial phagocytosis of protein aggregates
- Targeting microglial ER stress may reduce chronic neuroinflammation
BIP operates within a larger protein homeostasis network in the ER:
- ERdj co-chaperones: ERdj1-9 regulate BIP's ATPase activity and substrate binding
- ERAD components: BIP participates in ER-associated degradation
- Autophagy: BIP can be targeted to lysosomes for aggregate clearance
- ER-mitochondria contacts: BIP influences calcium exchange between organelles
Multiple therapeutic approaches target BIP modulation:
- BIP inducers: Compounds that upregulate BIP expression (e.g., TUDCA, sodium phenylbutyrate)
- BIP activity modulators: Small molecules that enhance BIP's chaperone function
- UPR modulators: Drugs that fine-tune the balance between adaptive and apoptotic UPR
- Gene therapy: Viral vectors for BIP overexpression in the brain
Several clinical trials have evaluated BIP-modulating compounds:
- TUDCA in ALS (completed, showing some benefit)
- Sodium phenylbutyrate in AD (completed)
- Combination therapies targeting multiple UPR branches (ongoing)
Key challenges in targeting BIP therapeutically include:
- Balancing adaptive UPR activation versus apoptotic signaling
- Achieving sufficient brain penetration with small molecules
- Ensuring proper timing of intervention in disease progression
- Avoiding disruption of normal protein homeostasis
flowchart TD
A["Normal ER Homeostasis"] --> B["BIP binds PERK/IRE1/ATF6"]
B --> C["UPR Signaling Inactive"]
D["ER Stress"] --> E["BIP releases PERK/IRE1/ATF6"]
E --> F["Three UPR Branches"]
F --> G1["PERK Branch"]
F --> G2["IRE1 Branch"]
F --> G3["ATF6 Branch"]
G1 --> H1["eIF2α磷酸化"]
H1 --> H2["ATF4翻译"]
H2 --> H3["CHOP表达/ apoptosis"]
G2 --> I1["IRE1寡聚化"]
I1 --> I2["XBP1剪接"]
I2 --> I3["ER chaperones上调"]
G3 --> J1["ATF6运送到高尔基体"]
J1 --> J2["ATF6蛋白水解切割"]
J2 --> J3["转录因子激活"]
H3 --> K["Pro-apoptotic signaling"]
I3 --> L["Adaptive response"]
J3 --> L
K --> M["Cell Death"]
L --> N["ER Homeostasis Restored"]
style M fill:#ff6b6b
style N fill:#51cf66